Overview of metformin: Special focus on metformin extended release

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 12, 2012, Pages 1797-1805

  Ali, Shamsa ^a   Fonseca, Vivian ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

Extended release metformin; Metformin; Metformin and cancer; Pharmacokinetics of metformin; T2DM

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIPID; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; ORGANIC CATION TRANSPORTER 1; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; EXTENDED RELEASE FORMULATION; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; IMMEDIATE RELEASE FORMULATION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER CELL; MEDLINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION;

ANIMALS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; METFORMIN; NEOPLASMS;

EID: 84864062799     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.705829     Document Type: Review

References (87)

1. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2010;2:1
2. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007;35(10):1956-1962
3. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994;112(2):671-675
4. Gusler G, Gorsline J, Levy G, et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001;41(6):655-661
5. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: A review. Crit Rev Ther Drug Carrier Syst 2003;20(6):459-497
6. Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007;35(8):1333-1340
7. Kennedy M, Chinwah P, Wade DN. A pharmacological method of measuring mouth caecal transit time in man. Br J Clin Pharmacol 1979;8(4):372-373
8. Gibaldi M, Levy G. Pharmacokinetics in clinical practice. I. concepts. JAMA 1976;235(17):1864-1867
9. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12(2):235-246
10. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44(7):721-729
11. Hong Y, Rohatagi S, Habtemariam B, et al. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008;48(6):696-707
12. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16(3):195-202
13. Rothman DL, Magnusson I, Katz LD, et al. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991;254(5031):573-576
14. Staehr P, Hother-Nielsen O, Beck-Nielsen H, et al. Hepatic autoregulation: Response of glucose production and gluconeogenesis to increased glycogenolysis. Am J Physiol Endocrinol Metab 2007;292(5):E1265-9
15. Roden M, Bernroider E. Hepatic glucose metabolism in humans-its role in health and disease. Best Pract Res Clin Endocrinol Metab 2003;17(3):365-383
16. Krssak M, Brehm A, Bernroider E, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004;53(12):3048-3056
17. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117(5):1422-1431
18. Van Leeuwen N, Nijpels G, Dekker JM, et al. The effect of genetic variation in OCT1, OCT2 and MATE1 on metformin treatment response. Diabetes 2011;60:A387
19. Wang Z-, Yin OQP, Tomlinson B, Chow MSS. OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet Genomics 2008;18(7):637-645
20. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86(3):299-306
21. Argaud D, Roth H, Wiernsperger N, Leverve XM. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993;213(3):1341-1348
22. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. synergism with insulin. Biochem Pharmacol 1988;37(22):4353-4358
23. Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 2011;93(4):891S-16
24. Zheng D, MacLean PS, Pohnert SC, et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001;91(3):1073-1078
25. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307(5708):384-387
26. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275(1):223-228
27. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348(Pt 3):607-614
28. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120(7):2355-2369
29. Zhou K, Bellenguez C, Spencer CCA, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43(2):117-120
30. Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152(12):4610-4619
31. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-(alpha) in mice. Diabetologia 2011;54(2):339-334
32. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27(6):1349-1357
33. Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8(3):327-323
34. Standeven KF, Ariens RA, Whitaker P, et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002;51(1):189-197
35. Chakrabarti R, Hocking ED, Fearnley GR. Fibrinolytic effect of metformin in coronary-artery disease. Lancet 1965;2(7406):256-259
36. Janka HU. Platelet and endothelial function tests during metformin treatment in diabetes mellitus (short communication). Horm Metab Res Suppl 1985;15:120-122
37. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA 1999;281(21):2005-2012
38. UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-865
39. UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-865
40. Goldstein BJ. Clinical translation of "a diabetes outcome progression trial": Adopt appropriate combination oral therapies in type 2 diabetes. J Clin Endocrinol Metab 2007;92(4):1226-1228
41. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103(6):491-497
42. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (glucophage(registered trademark) XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: RESULTS from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005;7(1):28-39
43. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-2443
44. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: A meta-analysis. Diabetes Obes Metab 2008;10 Suppl 1:1-7
45. Gonzalez-Ortiz M, Martinez-Abundis E, Ramos Zavala MG, et al. Combination of metformin extended release and glimepiride in a single dosage in type 2 diabetic patients with monotherapy failure: Clinical trial of efficacy and safety. J Diabetes 2011;3:268
46. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3(3):159-165
47. Linnebjerg H, Kothare PA, Skrivanek Z, et al. Exenatide: Effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med 2006;23(3):240-245
48. Goldstein BJ, Feinglos MN, Lunceford JK, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-1987
49. Stenlof K, Raz I, Neutel J, et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010;26(10):2355-2363
50. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009;11(6):611-622
51. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26(7):540-549
52. UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853
53. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-986
54. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29(1):79-81
55. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010;122(2):112-120
56. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29(4):759-764
57. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003;25(2):515-529
58. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. the multicenter metformin study group. N Engl J Med 1995;333(9):541-549
59. Dunn CJ, Peters DH. Metformin: A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49(5):721-749
60. Hermann LS, Schersten B, Bitzen P-, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study. Diabetes Care 1994;17(10):1100-1109
61. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73(6):1294-1301
62. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16(4):621-629
63. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004;6(2):133-156
64. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008;99(6):995-1000
65. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29(4 Pt 2):6S44-52
66. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(10):4649-4654
67. Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158(5):631-634
68. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84(5):489-497
69. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006;114(6):597-605
70. Ruggiero-Lopez D, Lecomte M, Moinet G, et al. Reaction of metformin with dicarbonyl compounds. possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999;58(11):1765-1773
71. Piga R, Naito Y, Kokura S, et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007;193(2):328-334
72. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: The distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005;183(2):259-267
73. Matsumoto K, Sera Y, Abe Y, et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004;64(3):225-228
74. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-258
75. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-1305
76. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32(9):1620-1625
77. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: zodiac-16. Diabetes Care 2010;33(2):322-326
78. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008;51(8):1552-1553
79. Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6(5):472-474
80. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15(8):651-656
81. Tomkin GH. Malabsorption of vitamin B12 in diabetic patients treated with phenformin: A comparison with metformin. Br Med J 1973;3(5882):673-675
82. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010;33(1):156-161
83. Ting RZ-, Szeto CC, Chan MH-, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166(18):1975- 1979
84. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333(9):550-554
85. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21(10):1659-1663
86. Assan R, Heuclin C, Ganeval D, et al. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia 1977;13(3):211-217
87. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: A review of 330 cases. Diabetologia 1978;14(2):75-87